As you’ve probably read by now, Roche Diabetes was brave enough to host a ‘Social Media Summit‘ for the second year in a row last week, inviting a group of diabetes bloggers and online advocates to commune and interact. Yes, this was an all-expenses-paid trip to Orlando, FL, for those who attended, but by no means a marketing spiel. In fact, I was delighted that representatives from the American Diabetes Association (ADA) and the American…Read more »
Hearsay is that Al Mann, CEO of MannKind Corp., is one of those people who’s either brilliant, crazy, or a combination thereof. Probably the latter. And I guess you’d have to be to keep pushing ahead on developing a powdered inhalable insulin product in the wake of Pfizer’s colossal flop Exubera.
I interviewed Al Mann last November (when their product Afrezza was still spelled with an ‘s’). I thought his claims about this new mealtime…
The research poster is a clever invention. It basically allows researchers to pack all the details of a study they’ve conducted — abstract, methodology, graphs and charts, overview of results — on a 30″ x 40″ piece of cardboard to show it off at scientific events, so that colleagues can walk by and absorb their work in 10 minutes or less. Over 1,600 posters like this were presented this year at the American Diabetes Association…Read more »
Thirty-seven diabetes bloggers and online advocates convened here in Florida Tuesday, hosted by Roche Diabetes, for the second annual Social Media Summit — a rare in-person gathering where we can exchange ideas over advocacy efforts and discuss how we’d like to “change the world,” or at least diabetes care in the United States.
This year, representatives from both the American Diabetes Association (ADA) and the American Association of Diabetes Educators (AADE) were invited to have…Read more »
There were a number of encouraging news announcements this week here in Florida about progress on the JDRF’s Artificial Pancreas Project. The most prominent of those is today’s unveiling of the results of the STAR 3 Trial (Sensor-Augmented Pump Therapy for A1C Reduction) that showed adults, teens and children achieving a 4x reduction in A1C levels using this tech-heavy therapy versus patients on injections.
The STAR study, sponsored by Medtronic, was conducted at 30 clinics…